Maria Sainz - Avanos Medical Independent Director
| AVNS Stock | USD 19.16 0.21 1.08% |
Director
Ms. Maria Degois Sainz serves as Independent Director of the Company. Ms. Sainz has served as the CEO of Aegea Medical, a medical device company in the womens health space focused on the development of technology for endometrial ablation, since May 2018. Prior to that, she served as the President and CEO of Cardiokinetix, a medical device company, from May 2012 until July 2017. She was the President and CEO of Concentric Medical, Inc., a medical technology company, from April 2008 until May 2012. In 2011, Concentric Medical was acquired by Stryker Corporationrationration, where she was named General Manager of the business unit of Stryker Neurovascular. Ms. Sainz led integration activities following the acquisition of Guidant Corporation by Boston Scientific from 2006 to 2008. She served as President of the Cardiac Surgery division of Guidant from February 2003 through July 2006. Ms. Sainz served as Vice President, Global Marketing for the Vascular Intervention division of Guidant from January 2001 through February 2003. Ms. Sainz served as Vice President of the Intermedics Cardiac Rhythm Management business of Guidant in Europe, from 1998 to 2001. Ms. Sainz also serves as a director of Orthofix International, N.V., and Iridex Corporationrationration. Ms. Sainz was selected to serve as a member of our Board of Directors due to her leadership experience as a chief executive officer, knowledge of, and experience in, the healthcare industry, international experience, and public company board experience. since 2015.
| Age | 55 |
| Tenure | 9 years |
| Address | 5405 Windward Parkway, Alpharetta, GA, United States, 30004 |
| Phone | 844 428 2667 |
| Web | https://avanos.com |
Maria Sainz Latest Insider Activity
Tracking and analyzing the buying and selling activities of Maria Sainz against Avanos Medical stock is an integral part of due diligence when investing in Avanos Medical. Maria Sainz insider activity provides valuable insight into whether Avanos Medical is net buyers or sellers over its current business cycle. Note, Avanos Medical insiders must abide by specific rules, including filing SEC forms every time they buy or sell Avanos Medical'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Maria Sainz over six months ago Acquisition by Maria Sainz of 1435000 shares of Hyperfine at 1.0 subject to Rule 16b-3 |
Avanos Medical Management Efficiency
The company has return on total asset (ROA) of 0.0208 % which means that it generated a profit of $0.0208 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0177 %, meaning that it created $0.0177 on every $100 dollars invested by stockholders. Avanos Medical's management efficiency ratios could be used to measure how well Avanos Medical manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to gain to 0 in 2024, despite the fact that Return On Tangible Assets are likely to grow to (0.09). At this time, Avanos Medical's Total Current Assets are comparatively stable compared to the past year. Intangibles To Total Assets is likely to gain to 0.63 in 2024, whereas Net Tangible Assets are likely to drop slightly above 181.9 M in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Kristina Wright | Paragon 28 | 47 | |
| Susan Siegel | Nevro Corp | 60 | |
| Cheryl Blanchard | Anika Therapeutics | 60 | |
| Filippo Passerini | Integer Holdings Corp | 63 | |
| Michael DeMane | Nevro Corp | 63 | |
| James Hinrichs | Integer Holdings Corp | 53 | |
| Sheila Antrum | Integer Holdings Corp | 62 | |
| David Hoffmeister | Glaukos Corp | 66 | |
| Charles Farkas | CONMED | 68 | |
| Martin Maxwell | Integer Holdings Corp | 62 | |
| Cheryl Capps | Integer Holdings Corp | 59 | |
| William Summers | Integer Holdings Corp | 70 | |
| Pamela Bailey | Integer Holdings Corp | 72 | |
| Aimee Weisner | Glaukos Corp | 51 | |
| Kevin OBoyle | Nevro Corp | 62 | |
| Fred Hite | Orthopediatrics Corp | 56 | |
| Brian Concannon | CONMED | 62 | |
| Donald Spence | Integer Holdings Corp | 67 | |
| Elizabeth Weatherman | Nevro Corp | 60 | |
| Mark Foley | Glaukos Corp | 55 | |
| Martha Aronson | CONMED | 53 | |
Management Performance
| Return On Equity | 0.0177 | ||||
| Return On Asset | 0.0208 |
Avanos Medical Leadership Team
Elected by the shareholders, the Avanos Medical's board of directors comprises two types of representatives: Avanos Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Avanos. The board's role is to monitor Avanos Medical's management team and ensure that shareholders' interests are well served. Avanos Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Avanos Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| John Cato, Vice Resources | ||
| S Mansbach, Senior Vice President Interim General Counsel, Corporate Secretary | ||
| William Haydon, Senior Vice President and General Manager, Pain Management | ||
| Moji James, Senior Vice President General Counsel | ||
| Patrick OLeary, Independent Director | ||
| Sigfrido Delgado, Senior Chain | ||
| Julie Shimer, Independent Director | ||
| Michelle Scharfenberg, Senior Vice President Chief Ethics and Compliance Officer | ||
| Gary Blackford, Independent Non-Executive Chairman of the Board | ||
| William Hawkins, Independent Director | ||
| David Ball, Senior Vice President - Global Supply Chain and Procurement | ||
| Mojirade James, Senior Vice President General Counsel, Corporate Secretary | ||
| Heidi Kunz, Independent Director | ||
| Lee Burnes, Clinical RD | ||
| Michael Greiner, Chief Financial Officer, Senior Vice President | ||
| Scott Galovan, Vice Development | ||
| Michael CPA, Senior CEO | ||
| Sudhakar Varshney, Senior Procurement | ||
| John Byrnes, Independent Director | ||
| Maria Sainz, Independent Director | ||
| David Crawford, VP Treasurer | ||
| Arjun Sarker, Senior Vice President - International | ||
| John Hurley, Principal Controller | ||
| Kerr Holbrook, Senior Vice President General Manager - Chronic Care | ||
| Joseph Woody, Chief Executive Officer, Director |
Avanos Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Avanos Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0177 | ||||
| Return On Asset | 0.0208 | ||||
| Profit Margin | 0.02 % | ||||
| Operating Margin | 0.1 % | ||||
| Current Valuation | 1 B | ||||
| Shares Outstanding | 45.96 M | ||||
| Shares Owned By Insiders | 2.94 % | ||||
| Shares Owned By Institutions | 96.00 % | ||||
| Number Of Shares Shorted | 552.33 K | ||||
| Price To Earning | 51.23 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Avanos Stock Analysis
When running Avanos Medical's price analysis, check to measure Avanos Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avanos Medical is operating at the current time. Most of Avanos Medical's value examination focuses on studying past and present price action to predict the probability of Avanos Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avanos Medical's price. Additionally, you may evaluate how the addition of Avanos Medical to your portfolios can decrease your overall portfolio volatility.